Login / Signup

Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial.

Martin HaluzíkAlice ChengDirk Müller-WielandJukka WesterbackaZsolt BosnyakFelipe LauandLydie Melas-MeltJanaka KarallieddeJulio RosenstockGeremia B Bolli
Published in: Diabetes, obesity & metabolism (2020)
Kidney function seems to affect the glucose-lowering effects of Gla-300 versus IDeg-100 in insulin-naïve T2D. Greater HbA1c reductions with Gla-300 without increase in hypoglycaemia risk, were observed in patients with eGFR <60 mL/min/1.73 m2 .
Keyphrases
  • type diabetes
  • glycemic control
  • blood glucose
  • small cell lung cancer
  • insulin resistance
  • cardiovascular disease
  • clinical trial
  • study protocol
  • epidermal growth factor receptor
  • tyrosine kinase
  • phase ii